Insilico Medicine, a clinical-stage generative artificial intelligence-driven biotechnology company, has formed what it describes as the industry’s first Longevity Board to provide scientific oversight and strategic guidance for AI-enabled aging research and drug discovery.
The board will oversee life models, biomarkers of aging, the identification of dual-purpose targets implicated in aging, longevity, and disease, and clinical development to validate the effects of therapeutics on hallmarks of aging using biomarkers and foundation models.
Initial members include Longevity Board Chairman Andrew Adams, PhD, Group Vice President of Molecular Discovery at Eli Lilly and Company; Michael Levitt, PhD, 2013 Nobel Laureate in Chemistry; Denitsa Milanova, PhD, Founder and CEO of Medici Therapeutics; Alex Zhavoronkov, PhD, Co-CEO of Insilico Medicine; Feng Ren, PhD, Co-CEO of Insilico Medicine; and C.Y. Leung, PhD, Healthcare Partner at Value Partners.
The initiative aims to bridge large pharmaceutical development and longevity science and to accelerate the translation of experimental longevity compounds into commercially viable medicines.
The company is listed on the Main Board of the Hong Kong Stock Exchange under the stock code 03696.HK and targets therapeutic areas including fibrosis, oncology, immunology, pain, and metabolic and obesity-related disorders.
